Skip to content
Beacon

NVOXDefiance Daily Target 2X Long NVO ETF

Take a bet1y track recordRanked #314 of 949 in this goal

Seeks daily investment results of 200% the daily percentage change in the share price of NVO.

By Defiance ETFs LLC · Launched 2024

Annual Cost

1.30%

#5,565 of 5,861 · expensive

Fund Size

$52M

#3,616 of 5,861 · mid-size

Return (1Y)Goal

-37.8%

Track Record

1 year

#3,874 of 5,861 · seasoned

Performance

Total-return NAV · USD
Growth of $10,000
$7,119-28.8%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Strategy

Leveraged

What it actually holds

By weight

Concentration

single-stock bet — holdings shown are derivatives collateral, not diversification

TREASURY BILL
18.0%
N/A
10.1%
First American Government Obli
9.8%
N/A
3.8%
N/A
2.9%
N/A
2.8%
N/A
2.6%
N/A
2.3%
N/A
1.7%

Asset allocation

Other
193.9%
Stocks
27.8%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
93.6%High

Year-on-year price swings

Max drawdown
-94.5%Severe

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Listing

Exchange
NYSE Arca

Full fund details

Objective
Seeks daily investment results of 200% the daily percentage change in the share price of NVO.
Strategy
Actively managed ETF aiming for 200% daily exposure to the share price of NVO using derivatives like swaps and options. Concentrated in the pharmaceutical industry.
Inception date
December 2, 2024
Fund family
Defiance ETFs LLC

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged single stock
Critical

Most of these lose money

These funds amplify one stock's daily move, then reset every day. More than half of them have lost money outright, and the daily reset plus financing costs drag roughly 9.5% a year off the return. The longer you hold, the more that compounding works against you.

Sources: Bessembinder, 'Leveraged Single-Stock ETFs' (SSRN 2025)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at NVOX. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

See other funds for this goal

Data updated on 2026-08-04